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ABSTRACT
Purpose: Many observational studies have reported a correlation between obesity and 
increased risk of thyroid malignancy. However, the relationship of obesity with aggressive 
features in papillary thyroid cancer (PTC) is controversial. We aimed to investigate whether 
the clinicopathological features of PTC are associated with obesity.
Methods: We reviewed the medical records of 210 PTC patients who were followed up 
over a period of 10 years and examined body mass index (BMI) and other biochemical and 
clinicopathological parameters. The relationships between BMI and these parameters were 
assessed by logistic regression models based on BMI quartile (Q). The mean follow-up 
duration was 135.6±14.8 (range, 120–151) months.
Results: BMI had a strong positive correlation with age (r=0.208; P=0.002) and tumor size 
(r=0.177; P=0.01). We also found that patients with a higher BMI tended to be older (P=0.011) 
and have elevated triglyceride concentration (P=0.006), fasting plasma glucose (P<0.001), and 
thyroid-stimulating hormone (P=0.035). According to pair-wise comparisons of BMI, tumor 
size was remarkably higher in patients in Q4 (overweight and obese) than in patients in Q2 
(normal weight) (P=0.01). In a multivariable-adjusted model, higher BMI was consistently 
significantly associated with larger tumor size (odds ratio, 1.433; 95% confidence interval, 
1.097–2.053; P=0.041). However, there was no significant difference in long-term disease 
status, such as recurrence, persistent disease, and disease-free status, by BMI (P=0.781).
Conclusion: Higher BMI (>26.4 kg/m2) was significantly correlated with larger tumor size, but 
not long-term disease status, in patients with PTC.
Keywords: Obesity; Body mass index; Thyroid cancer; Prognosis
INTRODUCTION
The global obesity prevalence has been increasing by approximately half a body mass index 
(BMI) unit per decade over the past three decades (1). The prevalence of various types of 
cancer has also increased during the same time period. There is a trend of an increase in the 
obese population in Asian countries, including Korea, due to westernized eating habits and 
lifestyle (2,3). Obesity is associated with an increased risk of a variety of different cancers, 
including esophageal, colon and rectum, breast, endometrium, kidney, and thyroid cancers 
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(4,5). Furthermore, obesity can also drive cancer progression, and has been estimated to 
account for 14% of all cancer deaths in men and 20% in women in the United States (6). A 
positive correlation between BMI and the rate of mortality has been noted in certain types of 
cancer, including esophageal, colon and rectum, liver, gallbladder, pancreas, endometrium, 
ovary, breast, and kidney cancers (6,7).
Papillary thyroid cancer (PTC) has increased rapidly worldwide in the past few decades. 
Exposure to ionizing radiation during childhood, family history, iodine intake, and diabetes 
are well-known genetic and environmental risk factors associated with thyroid carcinogenesis 
(3,8). Obesity has also been reported to be associated with an increased incidence of PTC 
(9,10). Furthermore, recent meta-analyses have indicated that a 5-kg/m2 increase in BMI is 
strongly associated with thyroid cancer (7).
Although a strong positive correlation between obesity and thyroid cancer has been 
epidemiologically reported, the underlying carcinogenic mechanism has not been fully 
evaluated. During obesity, biological mechanisms involving insulin, insulin-like growth 
factors, cytokines, inflammation, thyroid-stimulating hormone (TSH), sex steroids, sex 
steroid-binding globulin, and adipokines such as adiponectin and leptin may promote 
carcinogenesis (11,12). A few retrospective studies suggest that an increase in BMI is associated 
with aggressive clinical behaviors in PTC (12-14). However, in thyroid cancer, there is immense 
heterogeneity in tumor behavior between studies with regard to the association between 
obesity and tumor prognosis (10,15). In addition, these previous studies mainly analyzed 
western populations, with few studies being performed in Asia. Because the relationship 
between obesity and poor prognostic factors associated with PTC is still debatable, a large 
cohort study including Korean patients with long-term follow-up is needed.
The purpose of this study was to examine whether prognostic parameters in PTC are 
associated with obesity in a single Korean cohort. The BMI and prognostic parameters of 
patients with PTC who were followed up over a period of 10 years at a single institution were 
retrospectively reviewed.
MATERIALS AND METHODS
1. Study population
The medical records of patients diagnosed with PTC from January 2000 to December 2005 
at the Chungnam National University Hospital (Daejeon, Korea) with at least 10 years' 
follow-up were retrospectively reviewed. In this study, only patients with a first primary 
PTC were included. The exclusion criteria were as follows: <18 years old; a prior history 
of cancer; exposure to ionizing radiation during childhood and/or adolescence; thyroid 
cancer in first-degree relatives; renal, liver, or heart failure; diabetes mellitus; alcohol or 
cigarette consumption; pregnancy; or receiving medications that affect body weight (e.g., 
steroids). Patients with no information on biochemical parameters (TSH, free thyroxine 
[FT4], triglyceride [TG] concentration, fasting plasma glucose [FPG], total cholesterol [TC], 
high-density lipoprotein-cholesterol [HDL-C], and low-density lipoprotein-cholesterol 
[LDL-C]) or data of anthropometric factors (height and weight) before surgery that were used 
as confounding variables were also excluded. We also excluded non-conventional variants 
of PTC, including follicular variant PTC, because variants of PTC might have a confounding 
effect on our study. Finally, 210 patients were eligible for analysis in this study.
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We collected from the final pathology reports information related to tumor size, 
extrathyroidal extension (ETE), bilaterality, multiplicity, lymphovascular invasion (LVI), and 
pathological subtype of PTC. The extent of the disease was measured in terms of tumor-
node-metastasis (TNM) staging according to the Union for International Cancer Control/
American Joint Committee on Cancer (UICC/AJCC), 7th edition.
2. BMI calculation
At the baseline examination, weight and height were measured and BMI was calculated as 
weight in kilograms divided by height in meters squared (kg/m2). The height and weight of 
patients were measured at the time of operation. A 5-kg/m2 increase in BMI was used as a 
continuous variable in the initial models. At the same time, biochemical parameters and 
aggressive clinicopathological factors were analyzed.
Although the World Health Organization defines a BMI ≥25 as overweight and a BMI ≥30 as 
obese, most Asians, including Koreans, generally have a lower BMI and a higher percentage 
of body fat than Caucasians. Several modified BMI cut-off levels for Asians have been 
developed in Asian countries. However, there is currently no universal cut-off point for 
“overweight” across all Asian populations. In this study, we created our own BMI model for 
the study cohort. The cut-off points for BMI divided the range of probability distribution into 
contiguous intervals with equal probabilities. We classified patients into 4 groups by BMI 
quartiles (Qs) as follows: Q1 (underweight or lower limit of normal, <22 kg/m2), Q2 (normal, 
22–23.8 kg/m2), Q3 (upper limit of normal, 23.8–26.4 kg/m2), and Q4 (overweight and obese, 
>26.4 kg/m2). We also performed an analysis using the 4 BMI groups in which each BMI 
group was used as the reference category.
3. Statistical methods
Quantitative parameters are expressed as the mean±standard deviation or as the number 
(percentage). Differences between mean values were analyzed using the Student's t-test 
or 1-way analysis of variance (ANOVA), when appropriate. Comparisons between groups 
were made using the chi-square test or linear-by-linear association, as indicated in table 
legends. Trends according to BMI category were assessed using one-way ANOVA or linear-
by-linear association, as appropriate. Pearson's correlation coefficient was used to assess 
the association of 2 variables. The association between different variables and obesity was 
expressed in terms of the odds ratio (OR), with a 95% confidence interval (CI) (calculated 
by logistic regression) for multivariate analysis. P values <0.05 were considered statistically 
significant. All statistical analyses were performed using IBM SPSS Statistics 20.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
1. Baseline characteristics and prognosis
Patient characteristics are summarized in Table 1. A total of 210 PTC patients (183 women 
and 27 men) were enrolled. The mean age at diagnosis was 44.9±11.3 (range, 19–77) years. 
The mean BMI was 24.2±3.3 kg/m2, and the patients were grouped into the BMI groups as 
follows: 53 (25.2%) (Q1) were underweight or the lower limit of normal, 52 (24.8%) (Q2) were 
normal, 53 (25.2%) were the upper limit of normal, and 52 (24.8%) were overweight or obese 
(Fig. 1). The mean tumor size was 2.5±1.1 (range, 0.8–3.5) cm, and 76 (36.2%) of the tumors 
had ETE. The prevalences of central neck lymph node (LN) metastasis and lateral neck LN 
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metastasis were 25.7% (n=54) and 5.7% (n=12), respectively. About 1% of the patients had 
distant metastasis.
The mean follow-up duration was 135.6±14.8 (range, 120–151) months, recurrence occurred 
in 6 patients (2.9%), and the site of recurrence was the regional cervical area for 5 patients 
and the lung for 1 patient. The lateral neck LN was the most common recurrent site (4/6), 
and there was one case of thyroid bed recurrence. Persistent disease was found in 4 patients 
(2%). There was no significant difference in long-term disease status, such as recurrence, 
persistent disease, and disease-free status, according to BMI (P=0.781) (data not shown).
2. Association between BMI and clinical parameters
Table 2 shows the comparison of the biochemical parameters according to BMI. The higher 
BMI groups tended to be older (P=0.011) and have elevated TG (P=0.006), FPG (P<0.001), 
and TSH (P=0.035). In the overweight and obese group, a significant difference in aggressive 
tumor features was observed only for patients with larger tumors (P=0.034). We also 
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Table 1. Baseline characteristics
Variables Results (n=210)
Sex (male:female) 27:183 (12.9:87.1)
Age (yr) 44.9±11.3
TG (mg/dL) 124.5±6.3
TC (mg/dL) 183.3±2.6
FPG (mg/dL) 98.9±1.1
FT4 (ng/dL) 1.3±0.1
TSH (uIU/mL) 2.1±0.1
HDL-C (mg/dL) 45.6±2
LDL-C (mg/dL) 109.2±5.5
BMI (kg/m2) 24.2±3.3
Tumor size (cm) 2.5±1.1
Multifocality
Negative 170 (81)
Positive 40 (19)
ETE
Negative 134 (68.3)
Positive 76 (36.2)
Bilateral
Negative 180 (85.7)
Positive 30 (14.3)
LVI
Negative 86 (41)
Positive 124 (59)
T stage
T1 102 (48.6)
T2 20 (9.5)
T3 85 (40.5)
T4 3 (1.4)
N stage
N0 144 (68.6)
N1a 54 (25.7)
N1b 12 (5.7)
M stage
M0 208 (99)
M1 2 (1)
Data are presented as number (%) or mean±standard deviation.
TG = triglyceride; TC = total cholesterol; FPG = fasting plasma glucose; FT4 = free thyroxine; TSH = thyroid-
stimulating hormone; HDL-C = high-density lipoprotein-cholesterol; LDL-C = low-density lipoprotein-cholesterol; 
BMI = body mass index; ETE = extrathyroidal extension; LVI = lymphovascular invasion.
performed an analysis using pair-wise comparison to compare each BMI group as a reference 
group. According to group-wise comparisons, age (Q1 vs. Q3 and Q1 vs. Q4), serum TG (Q1 
vs. Q3 and Q1 vs. Q4), FPG (Q1 vs. Q2, Q1 vs. Q3, and Q1 vs. Q4), and TSH (Q1 vs. Q4) were 
significantly different between BMI groups. In terms of aggressive tumor parameters, only 
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Fig. 1. Cut-off points of BMI divided by the range of probability distribution into contiguous intervals with equal 
quartiles, as follows: Q1 (<22 kg/m2), Q2 (22–23.8 kg/m2), Q3 (23.8–26.4 kg/m2), and Q4 (>26.4 kg/m2). 
BMI = body mass index; Q = quartile.
Table 2. Comparison of the biochemical parameters and clinicopathological characteristics according to quartile of BMI (Q1–4)
Characteristics BMI (kg/m2) P value
Q1 (<22) Q2 (22–23.8) Q3 (23.8–26.4) Q4 (>26.4)
No. (%) 53 (25.2) 52 (24.8) 53 (25.2) 52 (24.8)
Sex (male:female) 7:46 (13.2:86.8) 5:47 (9.6:90.4) 8:45 (15.1:84.9) 7:45 (13.5:86.5) 0.764
Age (yr) 41.11±12.72 45.33±9.68 45.75±10.28 48.38±11.82 0.011*
TG (mg/dL) 95.14±50.23 115.19±66.65 153.35±111.70 138.93±95.57 0.006*
TC (mg/dL) 176.61±32.78 177.39±35.11 188.57±37.71 190.38±40.39 0.111*
FPG (mg/dL) 91.76±12.04 98.80±15.56 98.57±12.61 105.71±21.29 <0.001*
FT4 (ng/dL) 1.30±1.14 1.23±0.40 1.14±0.27 1.36±1.04 0.738*
TSH (uIU/mL) 2.51±1.91 1.85±1.34 2.38±1.99 1.69±1.14 0.035*
HDL-C (mg/dL) 47.91±14.36 43.90±11.45 48.40±8.72 40.55±8.15 0.390*
LDL-C (mg/dL) 113.4±30.88 92.0±9.53 115.32±29.92 104.08±36.62 0.646*
Tumor size (cm) 1.86±1.02 1.72±0.94 1.99±1.27 2.41±1.66 0.034*
Multifocality 8 (15.1) 11 (21.2) 9 (17.0) 12 (23.1) 0.416†
ETE 24 (45.3) 18 (34.6) 19 (35.8) 15 (28.8) 0.105†
Bilaterality 5 (9.4) 9 (17.3) 8 (15.1) 8 (15.4) 0.466†
LVI 29 (54.7) 33 (63.5) 35 (66.0) 27 (51.9) 0.860†
T stage 0.588†
T1 21 (39.6) 32 (61.5) 25 (47.2) 24 (46.2)
T2 5 (9.4) 1 (1.9) 7 (13.2) 7 (13.5)
T3 27 (50.9) 18 (34.6) 19 (35.8) 21 (40.4)
T4 0 (0) 1 (1.9) 2 (3.8) 0 (0)
N stage 0.625†
N0 35 (66.0) 37 (71.2) 34 (64.2) 38 (73.1)
N1 18 (34.0) 15 (28.8) 19 (35.8) 14 (26.9)
M stage 0.611†
M0 53 (100) 52 (100) 51 (96.2) 52 (100)
M1 0 (0) 0 (0) 2 (35.8) 0 (0)
Recurrence 9 (17.0) 11 (21.2) 5 (9.4) 13 (25.0)
Data are presented as number (%) or mean±standard deviation.
Q = quartile; BMI = body mass index; TG = triglyceride; TC = total cholesterol; FPG = fasting plasma glucose; FT4 = free thyroxine; TSH = thyroid-stimulating hormone; 
HDL-C = high-density lipoprotein-cholesterol; LDL-C = low-density lipoprotein-cholesterol; ETE = extrathyroidal extension; LVI = lymphovascular invasion.
*P values were calculated by One-way ANOVA; †P values were calculated by linear-by linear association.
tumor size was remarkably higher in Q4 (overweight and obese) than in Q2 (normal weight) 
(P=0.01) (Table 3).
To avoid arbitrary categorization, we analyzed BMI as a continuous variable. We found a 
strong positive correlation between BMI and age (r=0.208; P=0.002) (Fig. 2A). In this series 
of patients, a significant correlation between BMI and tumor size was also noted (r=0.177; 
P=0.001) (Fig. 2B).
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Table 3. Pair-wise comparison of the basic characteristics and clinicopathological characteristics among the four subgroups of BMI in patients with thyroid 
cancer (P values)
Characteristics BMI (kg/m2)
Q1 vs. Q2 Q1 vs. Q3 Q1 vs. Q4 Q2 vs. Q3 Q2 vs. Q4 Q3 vs. Q4
Sex* (male:female) 0.563 0.780 0.969 0.394 0.539 0.811
Age† (yr) 0.059 0.041 0.003 0.827 0.152 0.227
TG† 0.104 0.002 0.006 0.054 0.165 0.522
TC† 0.908 0.087 0.059 0.123 0.084 0.814
FPG† 0.012 0.002 0.003 0.783 0.064 0.077
FT4† 0.771 0.482 0.837 0.302 0.516 0.247
TSH† 0.052 0.742 0.011 0.130 0.523 0.041
HDL-C† 0.716 0.931 0.205 0.535 0.752 0.060
LDL-C † 0.097 0.892 0.568 0.222 0.388 0.478
Tumor size† (cm) 0.464 0.568 0.043 0.221 0.010 0.147
Multifocality* 0.420 0.791 0.298 0.586 0.813 0.435
ETE* 0.265 0.323 0.081 0.895 0.527 0.443
Bilaterality* 0.235 0.374 0.355 0.758 0.791 0.967
LVI* 0.362 0.233 0.774 0.782 0.234 0.141
T stage* 0.075 0.426 0.354 0.323 0.363 0.916
T1 vs. T2–4 0.025 0.433 0.499 0.139 0.116 0.917
T1–2 vs. T3–4 0.137 0.242 0.278 0.745 0.687 0.936
T1–3 vs. T4 0.310 0.153 (−) 0.569 0.315 0.157
Lymph node metastasis*
N0 vs. N1 0.572 0.839 0.433 0.443 0.827 0.325
M stage* (−) 0.153 (−) 0.157 (−) 0.157
Q = quartile; BMI = body mass index; TG = triglyceride; TC = total cholesterol; FPG = fasting plasma glucose; FT4 = free thyroxine; TSH = thyroid-stimulating hormone; 
HDL-C = high-density lipoprotein-cholesterol; LDL-C = low-density lipoprotein-cholesterol; ETE = extrathyroidal extension; LVI = lymphovascular invasion.
*P value calculated by Pearson χ2 test; †P value calculated byunpaired student's t-test.
r=0.177
P value=0.01
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Fig. 2. Correlation between BMI with a 5-kg/m2 increase and clinicopathologic factors in patients with papillary thyroid carcinoma. (A) Correlation between BMI 
and age. (B) Correlation between BMI and tumor size (r=Pearson's correlation coefficient). 
BMI = body mass index.
3.  Multivariable analysis of the association between obesity and 
clinicopathological parameters
To determine how strongly obesity was associated with clinicopathological parameters in 
PTC, we calculated the OR to predict factors in overweight or obese patients (BMI-Q4) by 
multivariable analysis. Table 4 shows the risk of aggressive tumor parameters in the higher 
BMI group (Q4). Q4 was strongly correlated with larger tumor size compared to Q1 and Q2. 
After adjusting for age and gender, the BMI-Q4 group had significantly higher odds of larger 
tumor size relative to the Q1 and Q2 groups (OR, 1.541; 95% CI, 1.174–2.167; P=0.013). After 
adjusting for TG, FPG, and TSH, higher BMI was consistently significantly associated with 
larger tumor size (OR, 1.433; 95% CI, 1.097–2.053; P=0.041).
179https://jes-online.org https://doi.org/10.16956/jes.2018.18.3.173
Obesity and Tumor Size in PTC
(continued to the next page)
Table 4. Multivariate analysis for BMI with aggressive clinicopathological features
Clinicopathological outcomes BMI-Q4 group
OR 95% CI P value
Adjusted for age at diagnosis and gender
Tumor size 1.541 1.174–2.167 0.013
Multifocal 1.215 0.424–3.478 0.717
ETE 0.421 0.176–1.008 0.052
Bilateral 1.331 0.380–4.661 0.655
LVI 0.866 0.388–1.931 0.725
N stage 0.704 0.294–1.684 0.430
TG 1.009 1.001–1.018 0.022
TC 1.008 0.996–1.019 0.184
FPG 1.045 1.015–1.076 0.003
FT4 1.349 0.789–2.305 0.274
TSH 0.661 0.479–0.913 0.012
HDL-C 1.015 0.866–1.190 0.853
LDL-C 0.970 0.928–1.014 0.178
Adjusted for age at diagnosis, gender, and TG
Tumor size 1.514 1.159–2.164 0.023
Multifocal 1.439 0.467–4.433 0.526
ETE 0.297 0.109–0.808 0.017
Bilateral 1.572 0.363–2.041 0.734
LVI 0.861 0.363–2.041 0.734
N stage 0.802 0.315–2.039 0.642
TC 1.004 0.992–1.016 0.518
FPG 1.037 1.007–1.068 0.017
FT4 1.037 0.741–2.349 0.347
TSH 0.663 0.475–0.925 0.016
HDL-C 1.051 0.869–1.270 0.609
LDL-C 0.971 0.929–1.016 0.202
Adjusted for age at diagnosis, gender, TG, and FPG
Tumor size 1.459 1.108–2.017 0.031
Multifocal 1.309 0.427–4.010 0.638
ETE 0.402 0.160–1.008 0.052
Bilateral 1.182 0.314–4.454 0.805
LVI 0.720 0.308–1.682 0.448
N stage 0.750 0.298–1.886 0.541
TG 1.009 1.001–1.098 0.033
TC 1.007 0.996–1.020 0.221
FT4 1.324 0.800–2.190 0.275
TSH 0.683 0.487–0.958 0.027
HDL-C 1.070 0.889–1.288 0.472
LDL-C 0.973 0.929–1.018 0.235
Adjusted for age at diagnosis, gender, TG, FPG, and TSH
Tumor size 1.433 1.097–2.053 0.041
Multifocal 0.862 0.263–2.828 0.807
ETE 0.381 0.145–1.001 0.050
Bilateral 1.054 0.268–4.140 0.940
DISCUSSION
Using data from thyroid cancer patients from a single center in Korea with long-term 
follow-up, we observed only tumor size significantly correlated with a high BMI. There was 
no association between BMI and any other aggressive oncological parameter. Furthermore, 
BMI was not a significant predictor of prognosis when evaluating recurrence and persistent 
disease status.
Obesity is now recognized as a major global health problem due to its association with 
increased risk of a variety of different cancer types. Recently, more epidemiologic studies 
have revealed a strong positive correlation between BMI and the risk of PTC (1-3). In a recent 
meta-analysis of 5 prospective studies in the United States, BMI was independently and 
positively associated with the risk of thyroid cancer in both men and women (16). Likewise, 
another cohort study revealed a potential link between early life factors related to growth and 
body weight and thyroid carcinogenesis (17). Recently, a large cohort study in Korea analyzed 
the national health insurance corporation cohort database including a total of 351,402 
individuals (men: 181,709, women: 169,693) aged over 20 years (3). This study showed that 
the risk of thyroid cancer was significantly associated with obesity in men and women. 
However, in subgroup analysis, the risk of thyroid cancer increased proportionally with 
increasing BMI in men, but not in women. There was a strong correlation with the prevalence 
of thyroid cancer among younger women (≤45 years), whereas only a weak relationship 
was observed in older women (>45 years).The authors proposed that estrogen was a 
significant risk factor contributing to thyroid cancer initiation, and that estrogen produced 
in the adipose tissue of postmenopausal women was more highly associated with thyroid 
cancer than the estrogen produced in the ovaries in premenopausal women. However, the 
mechanism of the interaction between obesity-related biological factors and the effects of 
these factors on PTC incidence remain unclear, and further study will be needed to confirm 
the correlation.
Although individual studies have made great efforts to evaluate the relationships between obesity 
and the oncological behaviors of PTC, they have provided conflicting results (10,12-15). Recently, 
a few studies have demonstrated that BMI is closely associated with aggressive oncologic features 
in PTC, such as tumor size, multiplicity, and advanced TNM stage (10,12-14). Particularly in 
women, BMI is strongly associated with ETE, multiplicity, and advanced T and TNM stages, 
indicating that obesity affects tumor behavior in PTC patients (12). Our study also showed 
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Clinicopathological outcomes BMI-Q4 group
OR 95% CI P value
LVI 1.420 0.565–3.564 0.456
N stage 0.610 0.233–1.596 0.314
TG 1.010 1.001–1.019 0.034
TC 1.003 0.990–1.016 0.700
FPG 1.035 1.001–1.070 0.043
FT4 1.084 0.602–1.952 0.789
HDL-C 1.044 0.865–1.260 0.652
LDL-C 0.970 0.925–1.016 0.201
BMI = body mass index; Q = quartile; OR = odds ratio; CI = confidence interval; ETE = extrathyroidal extension; 
LVI = lymphovascular invasion; TG = triglyceride; TC = total cholesterol; FPG = fasting plasma glucose; FT4 = free 
thyroxine; TSH = thyroid-stimulating hormone; HDL-C = high-density lipoprotein-cholesterol; LDL-C = low-density 
lipoprotein-cholesterol.
Table 4. (Continued) Multivariate analysis for BMI with aggressive clinicopathological features
that a higher BMI was strongly associated with larger tumor size and older age. According 
to our multivariable analysis, higher BMI was consistently significantly associated with 
larger tumor size. Although the identification of aggressive tumor features, such as tumor 
size, as predictive factors was statistically significant in our study, there is the possibility of 
other residual confounding factors affecting our results. Various analyses of the correlation 
between obesity and the oncological behavior of PTC should be performed in a large 
prospective cohort.
As there is insufficient clinical information available concerning the long-term prognosis of 
PTC in obese patients, no consistent results have been obtained (10,12-15,18). In our study, 
there was no significant difference in long-term disease status, such as recurrence, persistent 
disease, and disease-free status, among the different BMI groups. However, whether these 
results derived from biologic causes or statistical bias remains unclear. As we were unable to 
confirm a relationship between poor prognosis and BMI, careful intervention is warranted, 
and additional clinical analyses are needed.
Our study has several strengths. First, our follow-up period (over 10 years) was longer than 
that of other studies examining prognosis, and we examined three types of disease status, 
namely, recurrence, persistent disease, and disease-free status. Second, although the number 
of study subjects was relatively low, this study was well-characterized in a single Korean 
cohort. Therefore, our study was designed by well-organized data collection in a single 
medical center with a uniform laboratory method.
This study also has several limitations. First, our study cohort included only a small number of 
subjects, and we did not have enough patients with extreme BMIs, such as BMI ≥30 kg/m2 or BMI 
≤18.5 kg/m2. We created our own BMI model (BMI-Q group) for this study cohort. Therefore, our 
findings may not be applicable for extremely underweight or obese patients. Second, we did not 
have data on the obese or overweight duration. Further clinical data, including the percentage 
and distribution of body fat, physical activity, insulin resistance status, and inflammatory 
markers, would be helpful to discover potential biological mechanisms underlying the 
relationship between obesity and tumor behavior.
In our series, higher BMI (>26.4 kg/m2) was significantly correlated with larger tumor size. 
However, the prognosis of thyroid cancer was not associated with obesity in this cohort. It is 
crucial to thoroughly identify the biological mechanisms underlying the relationship between 
obesity and tumorigenesis to understand how obesity affects PTC.
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